Unique ID issued by UMIN | UMIN000019896 |
---|---|
Receipt number | R000012393 |
Scientific Title | Investigating basic information of skin toxicity associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer. |
Date of disclosure of the study information | 2015/11/23 |
Last modified on | 2016/02/27 07:32:46 |
Investigating basic information of skin toxicity associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer.
Usefulness of a topical moisturizer for cetuximab and panitumumab-associated skin toxicity in patients with CRC and head and neck cancer.
Investigating basic information of skin toxicity associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer.
Usefulness of a topical moisturizer for cetuximab and panitumumab-associated skin toxicity in patients with CRC and head and neck cancer.
Japan |
colorectal carcinoma and head and neck cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Dermatology | Oto-rhino-laryngology |
Malignancy
NO
Investigating basic information of skin toxicity by measuring sebum capacity and water content of the stratum corneum associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer.
Safety,Efficacy
sebum capacity, water content of the stratum corneum, duaring 6 weeks from cetuximab or Panitumumab contained chemotherapy started
skin findings(skin dryness,desquamation), subjective complaints duaring 6 weeks from cetuximab or Panitumumab contained chemotherapy started
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
YES
Institution is not considered as adjustment factor.
Central registration
2
Prevention
Medicine |
topical administration of heparinoid twice a day in six weeks
none
20 | years-old | <= |
Not applicable |
Male and Female
Colorectal cancer or head and neck cancer patient administered cetuximab or panitumumab
consent in writing
Patient treated with anti-EGFR antibody drugs before
Patient with retinoid and/or retinoid analog within two weeks of observation period
Patient with large skin problems such as burn, psoriasis, scleroderma
Patient with drug eruption within two weeks of observation period
Patient with hemorrhagic diseases such as hemophilia, thrombopenia, purpura
Patient regarded as ineligible for clinical study by investigator
40
1st name | |
Middle name | |
Last name | Shoichi Watanabe |
Nagoya city university
Dermatology
1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
052-851-5511
wshoichi@med.nagoya-cu.ac.jp
1st name | |
Middle name | |
Last name | Shoichi Watanabe |
Nagoya city university
Dermatology
1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
052-851-5511
wshoichi@med.nagoya-cu.ac.jp
Nagoya city university, Dermatology
spediffied non-profit corporation JASMIN
Other
NO
2015 | Year | 11 | Month | 23 | Day |
Unpublished
Completed
2012 | Year | 11 | Month | 29 | Day |
2013 | Year | 01 | Month | 22 | Day |
2015 | Year | 12 | Month | 31 | Day |
2015 | Year | 12 | Month | 31 | Day |
2015 | Year | 12 | Month | 31 | Day |
2016 | Year | 01 | Month | 31 | Day |
2015 | Year | 11 | Month | 23 | Day |
2016 | Year | 02 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012393